ABT-450/ritonavir

Phase 3

ABBOTT LABORATORIES (ABT)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

7 competitors in Hepatitis C

VRTXTelaprevir

Phase 3

4503.TInterferon alfacon-1

Drug Information

Target Indication

Hepatitis C

Clinical Trial

NCT01773070

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ABT

ABBOTT LABORATORIES

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)Phase 3

Human Immunodeficiency Virus Infections

Creon®Phase 3

Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Phleum pratense grass pollen allergen extractPhase 3

Seasonal Allergic Rhinitis

SA-001Phase 3

Exocrine Pancreatic Insufficiency, Chronic Pancreatitis

Niacin ER/Simvastatin TabletsPhase 3

Hyperlipidemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts